Results 11 to 20 of about 1,923,312 (279)

From Evidence to Delivery: Building Readiness for Maternal Respiratory Syncytial Virus Vaccination in Bangladesh [PDF]

Health Care Sci
Health Care Science, EarlyView.
Ridwana Maher Manna, Siobhan L. Johnstone, Pradip Chandra, Michelle J. Groome, Shams El Arifeen, Aniqa Tasnim Hossain   +5 more
wiley   +2 more sources

Airborne Virus Shedding of Respiratory Syncytial Virus Compared to Influenza A Virus in Hospitalized Patients [PDF]

Journal of Medical Virology, Volume 98, Issue 9, September 2026.
ABSTRACT Airborne transmission is an important route for the spread of respiratory viruses. To assess the potential for airborne shedding of influenza A virus (IAV) and respiratory syncytial virus (RSV), this study compared the presence of viral RNA in air samples collected near hospitalized patients.
Stijn de Man, Evert‐Jan Wils, Armand Paauw, Yesim Delice‐Ikiz, Wessel Hanselaar, Han J. C. Veltman, Gerda Doejaaren, Chelton van Laaren, Kim van den Bosch, Vincent Vermeule, Peter de Man, David S. Y. Ong   +11 more
wiley   +2 more sources

Qianjinweijingtang Decoction and Its Granule Inhibit Respiratory Syncytial Virus Infection and the Associated Inflammatory Response [PDF]

Chemistry &Biodiversity, Volume 23, Issue 9, September 2026.
The classical herbal formula Qianjinweijingtang in both decoction and granule forms, exhibits anti‐RSV activity. Isoliquiritigenin, quercetin, and gallic acid are identified as key active compounds. The mechanism involves interfering with viral entry and downregulating HIF‐1α and inflammatory responses, positioning the granule formulation as a ...
Chu‐Yi Liao, Mei‐Lan Yang, Ze‐Ping Chen, Bin Chen, Yu‐Jun Tang, Zhen Wang, Hui‐Nan Zhao, Su‐Hua Deng, Jin‐Hai Ye, Zhong Liu, Li‐Feng Chen, Man‐Mei Li   +11 more
wiley   +2 more sources

Complementary approaches to target human respiratory syncytial virus using small molecule ligands [PDF]

, 2012
In the current project, situated at the interface of chemistry and virology, complementary drug discovery approaches (high-throughput screening and structurebased drug design) have been exploited in order to discover novel small molecule inhibitors of ...
Lardeau, Charles-Hugues Claude Jean
core   +6 more sources

Estimating the National Disease Burden and Economic Burden of Respiratory Syncytial Virus (RSV) in Thailand [PDF]

Influenza and Other Respiratory Viruses, Volume 20, Issue 9, September 2026.
ABSTRACT Background Respiratory syncytial virus (RSV), a single‐stranded negative‐sense RNA virus, causes respiratory tract infections in children and adults, leading to hospitalization and mortality. However, the national disease burden and economic impact of RSV in Thailand remain undetermined.
Kansak Boonpattharatthiti, Chonnamet Techasaensiri, Wanatpreeya Phongsamart, Pilailuk Akkapaiboon Okada, Chanthawat Patikorn, Prabda Praphasiri, Teerapon Dhippayom, Nathorn Chaiyakunapruk   +7 more
wiley   +2 more sources

Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

MMWR. Morbidity and mortality weekly report, 2023
Respiratory syncytial virus (RSV) is a cause of severe respiratory illness in older adults. In May 2023, the Food and Drug Administration approved the first vaccines for prevention of RSV-associated lower respiratory tract disease in adults aged ≥60 ...
Michael Melgar, Amadea Britton, Lauren Roper, H. Talbot, Sarah S. Long, Camille N. Kotton, F. Havers   +6 more
semanticscholar   +1 more source

Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia

Journal of Allergy and Clinical Immunology: Global, 2023
Background: Infants with respiratory-syncytial virus bronchiolitis hospitalization are more likely to develop wheezing and subsequent asthma. Reportedly, palivizumab prophylaxis effectively prevents respiratory-syncytial virus hospitalization in high ...
Li-Ching Fang, MD, Jen-Yu Wang, MD, Hsin-Hui Yu, MD, PhD, Li-Chieh Wang, MD, PhD, Bor-Luen Chiang, MD, PhD   +4 more
doaj   +1 more source

Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

MMWR. Morbidity and mortality weekly report, 2023
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among U.S. infants. Nirsevimab (Bevfortus, Sanofi and AstraZeneca) is recommended to prevent RSV-associated lower respiratory tract infection (LRTI) in infants. In August 2023, the
K. Fleming-Dutra, Jefferson M. Jones, Lauren Roper, M. Prill, Ismael R. Ortega-Sanchez, Danielle L. Moulia, Megan Wallace, Monica Godfrey, K. Broder, Naomi K. Tepper, O. Brooks, Pablo J. Sánchez, Camille N. Kotton, Barbara E. Mahon, Sarah S. Long, M. McMorrow   +15 more
semanticscholar   +1 more source

Burden of respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis of the evidence from developed countries

European Respiratory Review, 2022
Background Respiratory syncytial virus (RSV) significantly impacts the health of older and high-risk adults (those with comorbidities). We aimed to synthesise the evidence on RSV disease burden and RSV-related healthcare utilisation in both populations ...
J. Nguyen-Van-Tam, Maureen O'Leary, E. Martin, E. Heijnen, Benoît Callendret, R. Fleischhackl, C. Comeaux, T. Tran, K. Weber   +8 more
semanticscholar   +1 more source

Respiratory Syncytial Virus: A Comprehensive Review of Transmission, Pathophysiology, and Manifestation

Cureus, 2023
With an increasing global incidence in children younger than the age of five, respiratory syncytial virus (RSV) is one of the most common viral respiratory infections worldwide. Despite the increasing number of cases among infants and young children, RSV
Jasndeep Kaler, Azhar Hussain, Kishan V. Patel, T. Hernandez, S. Ray   +4 more
semanticscholar   +1 more source